Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Robotics | 89 | 2020 | 124 | 19.540 |
Why?
|
Nephrectomy | 62 | 2020 | 123 | 14.720 |
Why?
|
Laparoscopy | 68 | 2018 | 172 | 14.610 |
Why?
|
Kidney Neoplasms | 49 | 2020 | 201 | 11.790 |
Why?
|
Cystectomy | 44 | 2020 | 105 | 9.680 |
Why?
|
Urinary Bladder Neoplasms | 37 | 2020 | 192 | 7.200 |
Why?
|
Urologic Surgical Procedures | 28 | 2019 | 64 | 6.350 |
Why?
|
Prostatectomy | 29 | 2019 | 83 | 6.170 |
Why?
|
Carcinoma, Transitional Cell | 20 | 2018 | 69 | 5.130 |
Why?
|
Ureter | 18 | 2018 | 38 | 4.650 |
Why?
|
Indocyanine Green | 10 | 2019 | 13 | 4.060 |
Why?
|
Prostatic Neoplasms | 29 | 2019 | 471 | 3.410 |
Why?
|
Postoperative Complications | 34 | 2019 | 780 | 3.160 |
Why?
|
Kidney Pelvis | 13 | 2018 | 17 | 3.140 |
Why?
|
Ureteral Neoplasms | 8 | 2015 | 11 | 3.010 |
Why?
|
Ureteral Obstruction | 12 | 2013 | 28 | 3.000 |
Why?
|
Humans | 214 | 2020 | 32114 | 3.000 |
Why?
|
Urinary Bladder | 13 | 2018 | 182 | 2.950 |
Why?
|
Male | 163 | 2020 | 19217 | 2.850 |
Why?
|
Coloring Agents | 7 | 2019 | 29 | 2.770 |
Why?
|
Carcinoma, Renal Cell | 11 | 2019 | 114 | 2.730 |
Why?
|
Middle Aged | 119 | 2020 | 11839 | 2.540 |
Why?
|
Aged | 99 | 2020 | 10314 | 2.410 |
Why?
|
Treatment Outcome | 71 | 2020 | 3306 | 2.300 |
Why?
|
Lymph Node Excision | 16 | 2018 | 89 | 2.230 |
Why?
|
Female | 127 | 2020 | 20015 | 2.210 |
Why?
|
Surgery, Computer-Assisted | 9 | 2019 | 53 | 2.180 |
Why?
|
Kidney Calculi | 10 | 2018 | 23 | 2.160 |
Why?
|
Urinary Diversion | 12 | 2020 | 26 | 2.110 |
Why?
|
Adult | 81 | 2019 | 9380 | 1.980 |
Why?
|
Kidney | 15 | 2019 | 518 | 1.750 |
Why?
|
Prostatic Hyperplasia | 5 | 2019 | 44 | 1.640 |
Why?
|
Aged, 80 and over | 36 | 2019 | 3990 | 1.580 |
Why?
|
Retrospective Studies | 48 | 2020 | 3510 | 1.560 |
Why?
|
Reconstructive Surgical Procedures | 8 | 2012 | 198 | 1.550 |
Why?
|
Retroperitoneal Space | 12 | 2018 | 20 | 1.320 |
Why?
|
Adrenalectomy | 7 | 2016 | 30 | 1.290 |
Why?
|
Prospective Studies | 25 | 2019 | 2283 | 1.280 |
Why?
|
Renal Insufficiency, Chronic | 7 | 2019 | 291 | 1.220 |
Why?
|
Neoplasm Invasiveness | 12 | 2019 | 190 | 1.190 |
Why?
|
Follow-Up Studies | 30 | 2019 | 2265 | 1.170 |
Why?
|
Adrenal Gland Neoplasms | 5 | 2016 | 15 | 1.160 |
Why?
|
Glomerular Filtration Rate | 17 | 2020 | 308 | 1.120 |
Why?
|
Length of Stay | 16 | 2019 | 314 | 1.100 |
Why?
|
Ureteral Calculi | 4 | 2018 | 7 | 1.070 |
Why?
|
Lymphography | 3 | 2014 | 4 | 1.060 |
Why?
|
Nomograms | 4 | 2020 | 32 | 1.020 |
Why?
|
Ureteral Diseases | 4 | 2018 | 8 | 0.990 |
Why?
|
Angiography | 2 | 2014 | 80 | 0.920 |
Why?
|
Young Adult | 19 | 2019 | 2665 | 0.880 |
Why?
|
Lymphatic Metastasis | 4 | 2019 | 166 | 0.880 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2019 | 154 | 0.840 |
Why?
|
Feasibility Studies | 16 | 2019 | 294 | 0.830 |
Why?
|
Neoplasm Staging | 15 | 2018 | 447 | 0.820 |
Why?
|
Warm Ischemia | 5 | 2020 | 9 | 0.780 |
Why?
|
Sutures | 2 | 2011 | 20 | 0.780 |
Why?
|
Magnetic Resonance Spectroscopy | 5 | 2009 | 83 | 0.770 |
Why?
|
Replantation | 2 | 2013 | 10 | 0.770 |
Why?
|
Urinary Bladder Fistula | 2 | 2012 | 2 | 0.760 |
Why?
|
Fistula | 2 | 2012 | 11 | 0.750 |
Why?
|
Fluorescence | 7 | 2016 | 20 | 0.740 |
Why?
|
Pelvis | 9 | 2018 | 61 | 0.730 |
Why?
|
Adolescent | 22 | 2019 | 3568 | 0.730 |
Why?
|
Pheochromocytoma | 3 | 2013 | 6 | 0.730 |
Why?
|
Patient Positioning | 4 | 2015 | 23 | 0.730 |
Why?
|
Urologic Neoplasms | 3 | 2019 | 14 | 0.700 |
Why?
|
Stents | 5 | 2018 | 177 | 0.700 |
Why?
|
Vesicovaginal Fistula | 3 | 2010 | 5 | 0.680 |
Why?
|
Prostate | 8 | 2013 | 68 | 0.670 |
Why?
|
Penile Neoplasms | 1 | 2019 | 6 | 0.660 |
Why?
|
Urologic Diseases | 1 | 2019 | 27 | 0.650 |
Why?
|
Monitoring, Intraoperative | 1 | 2019 | 42 | 0.650 |
Why?
|
Adenocarcinoma | 3 | 2013 | 308 | 0.640 |
Why?
|
Surgical Instruments | 5 | 2012 | 24 | 0.630 |
Why?
|
Urogenital Surgical Procedures | 2 | 2009 | 7 | 0.610 |
Why?
|
Kidney Diseases | 5 | 2016 | 249 | 0.610 |
Why?
|
Lymph Nodes | 5 | 2014 | 107 | 0.600 |
Why?
|
Renal Artery | 6 | 2019 | 47 | 0.600 |
Why?
|
Kidney Diseases, Cystic | 3 | 2018 | 13 | 0.590 |
Why?
|
Child | 16 | 2016 | 2442 | 0.580 |
Why?
|
Hemostasis, Surgical | 1 | 2016 | 13 | 0.560 |
Why?
|
Risk Factors | 18 | 2019 | 3880 | 0.550 |
Why?
|
Urinary Tract | 2 | 2015 | 22 | 0.540 |
Why?
|
Reperfusion Injury | 1 | 2016 | 49 | 0.530 |
Why?
|
Blood Loss, Surgical | 6 | 2018 | 49 | 0.530 |
Why?
|
Proteinuria | 1 | 2016 | 59 | 0.520 |
Why?
|
Ureterostomy | 3 | 2010 | 4 | 0.520 |
Why?
|
Urinary Catheterization | 1 | 2015 | 16 | 0.510 |
Why?
|
Time Factors | 12 | 2019 | 2151 | 0.500 |
Why?
|
Ureteroscopy | 3 | 2006 | 6 | 0.500 |
Why?
|
Hysterectomy | 4 | 2009 | 46 | 0.490 |
Why?
|
Perioperative Care | 5 | 2018 | 59 | 0.490 |
Why?
|
Sarcopenia | 1 | 2015 | 64 | 0.480 |
Why?
|
Preoperative Period | 5 | 2019 | 35 | 0.480 |
Why?
|
Clinical Competence | 4 | 2013 | 333 | 0.470 |
Why?
|
Prognosis | 11 | 2018 | 1497 | 0.460 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2020 | 367 | 0.460 |
Why?
|
Cystostomy | 2 | 2012 | 5 | 0.460 |
Why?
|
Infrared Rays | 2 | 2016 | 18 | 0.460 |
Why?
|
Survival Rate | 8 | 2019 | 877 | 0.450 |
Why?
|
Lymphoid Tissue | 1 | 2013 | 10 | 0.450 |
Why?
|
Urethra | 4 | 2011 | 102 | 0.450 |
Why?
|
Patient Selection | 7 | 2019 | 276 | 0.440 |
Why?
|
Program Evaluation | 2 | 2011 | 186 | 0.440 |
Why?
|
Lymphocytes | 1 | 2013 | 57 | 0.440 |
Why?
|
Adenoma | 1 | 2013 | 35 | 0.430 |
Why?
|
Vesico-Ureteral Reflux | 1 | 2013 | 20 | 0.430 |
Why?
|
Kidney Transplantation | 3 | 2015 | 517 | 0.430 |
Why?
|
Neutrophils | 1 | 2013 | 106 | 0.430 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 145 | 0.420 |
Why?
|
Uterine Cervical Diseases | 1 | 2012 | 2 | 0.420 |
Why?
|
Predictive Value of Tests | 7 | 2019 | 876 | 0.420 |
Why?
|
Constriction | 7 | 2019 | 12 | 0.410 |
Why?
|
Erectile Dysfunction | 2 | 2018 | 51 | 0.400 |
Why?
|
Uremia | 2 | 2011 | 9 | 0.400 |
Why?
|
Wound Healing | 2 | 2010 | 185 | 0.390 |
Why?
|
Suture Techniques | 1 | 2011 | 61 | 0.380 |
Why?
|
Intraoperative Care | 1 | 2011 | 48 | 0.380 |
Why?
|
Kidney Failure, Chronic | 2 | 2019 | 543 | 0.380 |
Why?
|
Nephrostomy, Percutaneous | 7 | 2016 | 17 | 0.380 |
Why?
|
Risk Assessment | 11 | 2019 | 1429 | 0.380 |
Why?
|
Cesarean Section | 1 | 2012 | 112 | 0.380 |
Why?
|
Peritoneum | 3 | 2018 | 33 | 0.370 |
Why?
|
Mononeuropathies | 1 | 2010 | 2 | 0.370 |
Why?
|
Urothelium | 1 | 2011 | 55 | 0.370 |
Why?
|
Cystoscopy | 4 | 2014 | 27 | 0.370 |
Why?
|
Postoperative Period | 4 | 2019 | 97 | 0.360 |
Why?
|
Urinary Bladder Calculi | 1 | 2010 | 2 | 0.350 |
Why?
|
Forecasting | 5 | 2019 | 143 | 0.350 |
Why?
|
Urinary Fistula | 1 | 2009 | 2 | 0.350 |
Why?
|
Disease Progression | 4 | 2017 | 594 | 0.350 |
Why?
|
Penis | 2 | 2010 | 35 | 0.350 |
Why?
|
Pyonephrosis | 1 | 2009 | 1 | 0.340 |
Why?
|
Drainage | 3 | 2016 | 72 | 0.340 |
Why?
|
Lower Extremity | 1 | 2010 | 100 | 0.340 |
Why?
|
Survival Analysis | 5 | 2018 | 483 | 0.340 |
Why?
|
Urogenital System | 1 | 2009 | 9 | 0.340 |
Why?
|
Uterine Diseases | 1 | 2009 | 22 | 0.330 |
Why?
|
Intraoperative Complications | 3 | 2019 | 56 | 0.320 |
Why?
|
Cohort Studies | 8 | 2019 | 1817 | 0.320 |
Why?
|
Equipment Design | 5 | 2011 | 171 | 0.320 |
Why?
|
Databases, Factual | 6 | 2019 | 355 | 0.320 |
Why?
|
Urinary Incontinence | 2 | 2019 | 47 | 0.310 |
Why?
|
Lithotripsy | 5 | 2007 | 11 | 0.310 |
Why?
|
Exosomes | 2 | 2019 | 43 | 0.310 |
Why?
|
Vena Cava, Inferior | 3 | 2019 | 30 | 0.300 |
Why?
|
Anastomosis, Surgical | 4 | 2011 | 58 | 0.300 |
Why?
|
Propensity Score | 5 | 2020 | 39 | 0.300 |
Why?
|
Granuloma, Foreign-Body | 2 | 2010 | 7 | 0.290 |
Why?
|
Ischemia | 4 | 2019 | 98 | 0.290 |
Why?
|
Lymphangioma | 1 | 2006 | 7 | 0.280 |
Why?
|
Urachus | 1 | 2006 | 3 | 0.270 |
Why?
|
Postoperative Care | 6 | 2018 | 76 | 0.270 |
Why?
|
Carcinoma | 2 | 2004 | 91 | 0.270 |
Why?
|
Kidney Calices | 1 | 2006 | 4 | 0.270 |
Why?
|
Penile Erection | 1 | 2005 | 21 | 0.260 |
Why?
|
Urography | 4 | 2009 | 15 | 0.260 |
Why?
|
Severity of Illness Index | 5 | 2019 | 881 | 0.250 |
Why?
|
Multivariate Analysis | 6 | 2018 | 684 | 0.250 |
Why?
|
Preoperative Care | 4 | 2016 | 114 | 0.250 |
Why?
|
Logistic Models | 5 | 2019 | 783 | 0.250 |
Why?
|
Tuberculosis, Urogenital | 1 | 2004 | 2 | 0.240 |
Why?
|
Comorbidity | 2 | 2017 | 566 | 0.240 |
Why?
|
Epididymis | 1 | 2004 | 9 | 0.240 |
Why?
|
Age Factors | 3 | 2018 | 1189 | 0.240 |
Why?
|
Infertility, Male | 1 | 2004 | 24 | 0.230 |
Why?
|
Iliac Vein | 1 | 2004 | 8 | 0.230 |
Why?
|
Prostate-Specific Antigen | 5 | 2008 | 62 | 0.230 |
Why?
|
Emigrants and Immigrants | 2 | 2016 | 244 | 0.230 |
Why?
|
Postural Balance | 1 | 2016 | 182 | 0.230 |
Why?
|
Apolipoproteins | 2 | 2016 | 200 | 0.220 |
Why?
|
Pesticides | 1 | 2016 | 199 | 0.220 |
Why?
|
Proportional Hazards Models | 3 | 2015 | 753 | 0.220 |
Why?
|
Renal Insufficiency | 3 | 2019 | 58 | 0.220 |
Why?
|
Lipoproteins, HDL | 2 | 2016 | 251 | 0.220 |
Why?
|
Vascular Surgical Procedures | 1 | 2004 | 88 | 0.220 |
Why?
|
Occupational Exposure | 1 | 2016 | 232 | 0.220 |
Why?
|
Adrenal Glands | 1 | 2002 | 4 | 0.210 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2003 | 82 | 0.210 |
Why?
|
Transients and Migrants | 1 | 2016 | 297 | 0.210 |
Why?
|
ROC Curve | 4 | 2019 | 164 | 0.200 |
Why?
|
Renal Veins | 3 | 2016 | 7 | 0.200 |
Why?
|
Disease-Free Survival | 4 | 2019 | 317 | 0.200 |
Why?
|
Magnetic Resonance Imaging | 5 | 2009 | 1328 | 0.200 |
Why?
|
Radiography | 2 | 2015 | 376 | 0.200 |
Why?
|
Sensitivity and Specificity | 5 | 2014 | 582 | 0.200 |
Why?
|
Diagnosis, Differential | 3 | 2013 | 517 | 0.200 |
Why?
|
Brain Neoplasms | 2 | 2007 | 638 | 0.200 |
Why?
|
Candidiasis | 1 | 2020 | 5 | 0.190 |
Why?
|
Pyelonephritis | 1 | 2020 | 9 | 0.180 |
Why?
|
Gram-Positive Bacterial Infections | 1 | 2020 | 12 | 0.180 |
Why?
|
Emphysema | 1 | 2020 | 12 | 0.180 |
Why?
|
United States | 6 | 2019 | 3976 | 0.180 |
Why?
|
Urology | 1 | 2020 | 31 | 0.180 |
Why?
|
Phenylthiohydantoin | 1 | 2019 | 7 | 0.170 |
Why?
|
Qa-SNARE Proteins | 1 | 2019 | 6 | 0.170 |
Why?
|
Hispanic Americans | 1 | 2016 | 940 | 0.170 |
Why?
|
Neoadjuvant Therapy | 1 | 2019 | 67 | 0.160 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2019 | 190 | 0.160 |
Why?
|
Thrombosis | 1 | 2019 | 73 | 0.160 |
Why?
|
Tumor Virus Infections | 1 | 2018 | 21 | 0.160 |
Why?
|
Polyomavirus Infections | 1 | 2018 | 21 | 0.160 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2010 | 20 | 0.150 |
Why?
|
Endoscopy | 1 | 2018 | 58 | 0.150 |
Why?
|
Hospital Costs | 1 | 2018 | 38 | 0.150 |
Why?
|
Costs and Cost Analysis | 2 | 2009 | 100 | 0.150 |
Why?
|
Antineoplastic Agents | 2 | 2019 | 608 | 0.150 |
Why?
|
Reoperation | 4 | 2019 | 226 | 0.150 |
Why?
|
Incidence | 4 | 2019 | 1199 | 0.150 |
Why?
|
Placenta | 1 | 2018 | 74 | 0.150 |
Why?
|
Decision Support Techniques | 1 | 2018 | 128 | 0.140 |
Why?
|
Kidney Function Tests | 2 | 2016 | 107 | 0.140 |
Why?
|
Laparoscopes | 2 | 2009 | 3 | 0.140 |
Why?
|
Probability | 3 | 2007 | 159 | 0.140 |
Why?
|
Mitochondrial Diseases | 1 | 2016 | 11 | 0.140 |
Why?
|
Intraoperative Period | 1 | 2016 | 42 | 0.140 |
Why?
|
Protective Agents | 1 | 2016 | 4 | 0.140 |
Why?
|
Organ Size | 2 | 2015 | 218 | 0.140 |
Why?
|
India | 5 | 2008 | 61 | 0.140 |
Why?
|
Models, Theoretical | 1 | 2017 | 137 | 0.130 |
Why?
|
Administration, Oral | 1 | 2016 | 187 | 0.130 |
Why?
|
Urinary Calculi | 2 | 2006 | 7 | 0.130 |
Why?
|
Drug Administration Schedule | 1 | 2016 | 276 | 0.130 |
Why?
|
Hypertension | 3 | 2019 | 960 | 0.130 |
Why?
|
Psoas Muscles | 1 | 2015 | 19 | 0.130 |
Why?
|
Case-Control Studies | 4 | 2018 | 898 | 0.130 |
Why?
|
North Carolina | 2 | 2016 | 1538 | 0.130 |
Why?
|
Recurrence | 4 | 2010 | 263 | 0.130 |
Why?
|
Stem Cells | 1 | 2018 | 313 | 0.130 |
Why?
|
Double-Blind Method | 1 | 2016 | 525 | 0.120 |
Why?
|
Risk | 1 | 2016 | 321 | 0.120 |
Why?
|
Creatinine | 2 | 2013 | 195 | 0.120 |
Why?
|
Premedication | 1 | 2014 | 13 | 0.120 |
Why?
|
Mesangial Cells | 1 | 2014 | 10 | 0.120 |
Why?
|
Diabetes Mellitus | 2 | 2018 | 412 | 0.120 |
Why?
|
Reproducibility of Results | 3 | 2018 | 765 | 0.120 |
Why?
|
Kidney Glomerulus | 1 | 2014 | 30 | 0.120 |
Why?
|
Kidney Tubules, Proximal | 1 | 2014 | 40 | 0.120 |
Why?
|
Analysis of Variance | 2 | 2013 | 464 | 0.120 |
Why?
|
Thiazolidinediones | 1 | 2014 | 47 | 0.110 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 1 | 2013 | 19 | 0.110 |
Why?
|
Neoplasm, Residual | 1 | 2013 | 25 | 0.110 |
Why?
|
Tumor Burden | 1 | 2013 | 58 | 0.110 |
Why?
|
Epinephrine | 1 | 2013 | 40 | 0.110 |
Why?
|
Hyperplasia | 1 | 2013 | 41 | 0.110 |
Why?
|
Combined Modality Therapy | 4 | 2010 | 560 | 0.110 |
Why?
|
Pilot Projects | 2 | 2013 | 548 | 0.110 |
Why?
|
Constriction, Pathologic | 1 | 2013 | 46 | 0.110 |
Why?
|
Dissection | 1 | 2012 | 17 | 0.110 |
Why?
|
RNA, Messenger | 1 | 2014 | 508 | 0.100 |
Why?
|
Body Mass Index | 1 | 2016 | 923 | 0.100 |
Why?
|
Urinary Tract Infections | 1 | 2012 | 46 | 0.100 |
Why?
|
Europe | 3 | 2019 | 82 | 0.100 |
Why?
|
Patient Readmission | 3 | 2019 | 126 | 0.100 |
Why?
|
Pregnancy Complications | 1 | 2012 | 105 | 0.100 |
Why?
|
Dioxanes | 1 | 2011 | 6 | 0.100 |
Why?
|
Obesity | 1 | 2019 | 1176 | 0.100 |
Why?
|
African Americans | 1 | 2018 | 1425 | 0.100 |
Why?
|
Statistics, Nonparametric | 1 | 2011 | 130 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 3 | 2006 | 919 | 0.090 |
Why?
|
Ablation Techniques | 1 | 2011 | 25 | 0.090 |
Why?
|
Biopsy | 4 | 2014 | 259 | 0.090 |
Why?
|
Polyesters | 1 | 2011 | 76 | 0.090 |
Why?
|
Polymers | 1 | 2011 | 64 | 0.090 |
Why?
|
Operating Rooms | 1 | 2011 | 35 | 0.090 |
Why?
|
Mineral Oil | 1 | 2010 | 4 | 0.090 |
Why?
|
Sclerosis | 1 | 2010 | 10 | 0.090 |
Why?
|
Physicians | 1 | 2013 | 159 | 0.090 |
Why?
|
Ganglioneuroma | 1 | 2010 | 2 | 0.090 |
Why?
|
Paraganglioma | 1 | 2010 | 5 | 0.090 |
Why?
|
Urolithiasis | 2 | 2007 | 7 | 0.090 |
Why?
|
Neurilemmoma | 1 | 2010 | 16 | 0.090 |
Why?
|
Cystotomy | 1 | 2010 | 1 | 0.090 |
Why?
|
Retroperitoneal Neoplasms | 1 | 2010 | 18 | 0.090 |
Why?
|
Algorithms | 2 | 2011 | 495 | 0.090 |
Why?
|
Catheter Ablation | 1 | 2010 | 67 | 0.090 |
Why?
|
Incidental Findings | 1 | 2010 | 25 | 0.090 |
Why?
|
Cost-Benefit Analysis | 2 | 2016 | 186 | 0.090 |
Why?
|
Mesocolon | 1 | 2009 | 1 | 0.080 |
Why?
|
Pain Measurement | 2 | 2007 | 350 | 0.080 |
Why?
|
Vaginal Fistula | 1 | 2008 | 2 | 0.080 |
Why?
|
Biopsy, Needle | 3 | 2005 | 93 | 0.080 |
Why?
|
Tissue Adhesions | 1 | 2008 | 9 | 0.080 |
Why?
|
Gynecologic Surgical Procedures | 1 | 2009 | 47 | 0.080 |
Why?
|
Nephrons | 2 | 2018 | 10 | 0.080 |
Why?
|
Retreatment | 1 | 2008 | 41 | 0.080 |
Why?
|
Anesthesia | 1 | 2009 | 64 | 0.080 |
Why?
|
Urethral Stricture | 1 | 2008 | 31 | 0.080 |
Why?
|
Animals | 4 | 2018 | 7542 | 0.080 |
Why?
|
Seminal Vesicles | 2 | 2005 | 3 | 0.080 |
Why?
|
Intubation, Gastrointestinal | 1 | 2008 | 11 | 0.080 |
Why?
|
Developing Countries | 1 | 2008 | 48 | 0.080 |
Why?
|
Program Development | 1 | 2008 | 97 | 0.070 |
Why?
|
Citric Acid | 2 | 2005 | 6 | 0.070 |
Why?
|
Fellowships and Scholarships | 1 | 2008 | 52 | 0.070 |
Why?
|
Receptor, erbB-2 | 1 | 2008 | 65 | 0.070 |
Why?
|
Republic of Korea | 2 | 2019 | 12 | 0.070 |
Why?
|
Carboplatin | 1 | 2007 | 48 | 0.070 |
Why?
|
Paclitaxel | 1 | 2007 | 67 | 0.070 |
Why?
|
Punctures | 1 | 2006 | 33 | 0.070 |
Why?
|
Models, Economic | 1 | 2006 | 20 | 0.070 |
Why?
|
Surgical Procedures, Operative | 1 | 2007 | 84 | 0.070 |
Why?
|
Cell Line, Tumor | 2 | 2019 | 726 | 0.070 |
Why?
|
Analgesics | 1 | 2007 | 109 | 0.070 |
Why?
|
Citrates | 1 | 2006 | 5 | 0.070 |
Why?
|
Urogenital Abnormalities | 1 | 2006 | 3 | 0.070 |
Why?
|
Rare Diseases | 1 | 2006 | 21 | 0.070 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2006 | 53 | 0.070 |
Why?
|
Software | 1 | 2006 | 123 | 0.070 |
Why?
|
Flank Pain | 1 | 2005 | 1 | 0.070 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2008 | 261 | 0.070 |
Why?
|
Adrenal Gland Diseases | 1 | 2005 | 1 | 0.070 |
Why?
|
Pain, Postoperative | 1 | 2007 | 178 | 0.060 |
Why?
|
Child, Preschool | 4 | 2016 | 1270 | 0.060 |
Why?
|
Orchiectomy | 1 | 2004 | 12 | 0.060 |
Why?
|
Flutamide | 1 | 2004 | 5 | 0.060 |
Why?
|
Immunohistochemistry | 2 | 2005 | 538 | 0.060 |
Why?
|
Quality of Life | 1 | 2011 | 946 | 0.060 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2004 | 42 | 0.060 |
Why?
|
Pain | 1 | 2007 | 288 | 0.060 |
Why?
|
Urinary Reservoirs, Continent | 1 | 2004 | 3 | 0.060 |
Why?
|
Creatine | 1 | 2003 | 5 | 0.060 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2004 | 23 | 0.060 |
Why?
|
Protons | 1 | 2003 | 23 | 0.060 |
Why?
|
Choline | 1 | 2003 | 14 | 0.060 |
Why?
|
Odds Ratio | 2 | 2016 | 472 | 0.060 |
Why?
|
Vagina | 1 | 2004 | 59 | 0.060 |
Why?
|
Disease Models, Animal | 2 | 2018 | 1022 | 0.060 |
Why?
|
Uterus | 1 | 2004 | 103 | 0.060 |
Why?
|
Cells, Cultured | 2 | 2016 | 834 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 458 | 0.050 |
Why?
|
Equipment Reuse | 1 | 2002 | 5 | 0.050 |
Why?
|
Muscle, Smooth | 1 | 2003 | 68 | 0.050 |
Why?
|
Pregnancy | 2 | 2018 | 997 | 0.050 |
Why?
|
Physical Examination | 2 | 2016 | 92 | 0.050 |
Why?
|
Unnecessary Procedures | 1 | 2002 | 16 | 0.050 |
Why?
|
Swine | 2 | 2016 | 215 | 0.050 |
Why?
|
Wounds and Injuries | 1 | 2004 | 253 | 0.050 |
Why?
|
Delayed Diagnosis | 1 | 2020 | 15 | 0.050 |
Why?
|
Fatal Outcome | 1 | 2020 | 83 | 0.050 |
Why?
|
Fear | 1 | 2020 | 48 | 0.040 |
Why?
|
Muscles | 1 | 2020 | 62 | 0.040 |
Why?
|
Ohio | 1 | 2019 | 58 | 0.040 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2019 | 104 | 0.040 |
Why?
|
Retrospective Moral Judgment | 1 | 2018 | 1 | 0.040 |
Why?
|
Demography | 2 | 2010 | 110 | 0.040 |
Why?
|
Sexual Behavior, Animal | 1 | 2018 | 9 | 0.040 |
Why?
|
JC Virus | 1 | 2018 | 20 | 0.040 |
Why?
|
Chemokine CXCL12 | 1 | 2018 | 25 | 0.040 |
Why?
|
Infant | 2 | 2016 | 1062 | 0.040 |
Why?
|
Urodynamics | 1 | 2018 | 37 | 0.040 |
Why?
|
Imaging, Three-Dimensional | 1 | 2019 | 132 | 0.040 |
Why?
|
Linear Models | 1 | 2019 | 449 | 0.040 |
Why?
|
Diabetes Complications | 1 | 2019 | 177 | 0.040 |
Why?
|
International Cooperation | 1 | 2017 | 28 | 0.040 |
Why?
|
Recovery of Function | 1 | 2019 | 199 | 0.040 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2017 | 19 | 0.040 |
Why?
|
Quality Control | 1 | 2017 | 44 | 0.040 |
Why?
|
Cell Survival | 1 | 2018 | 285 | 0.040 |
Why?
|
Overweight | 1 | 2019 | 280 | 0.040 |
Why?
|
Genotype | 1 | 2018 | 733 | 0.040 |
Why?
|
Macaca fascicularis | 1 | 2018 | 434 | 0.040 |
Why?
|
Lipids | 1 | 2018 | 232 | 0.030 |
Why?
|
Evidence-Based Medicine | 1 | 2018 | 218 | 0.030 |
Why?
|
Treatment Failure | 1 | 2016 | 162 | 0.030 |
Why?
|
Sex Factors | 1 | 2018 | 667 | 0.030 |
Why?
|
Magnesium Compounds | 2 | 2005 | 2 | 0.030 |
Why?
|
Calcium Oxalate | 2 | 2005 | 3 | 0.030 |
Why?
|
Cell Proliferation | 1 | 2018 | 604 | 0.030 |
Why?
|
Phosphates | 2 | 2005 | 25 | 0.030 |
Why?
|
African Continental Ancestry Group | 1 | 2016 | 363 | 0.030 |
Why?
|
Uric Acid | 2 | 2005 | 27 | 0.030 |
Why?
|
Fascia | 2 | 2005 | 10 | 0.030 |
Why?
|
Podocytes | 1 | 2014 | 20 | 0.030 |
Why?
|
Biomedical Research | 1 | 2016 | 156 | 0.030 |
Why?
|
Microscopy, Fluorescence | 1 | 2014 | 88 | 0.030 |
Why?
|
Signal Transduction | 1 | 2018 | 682 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2016 | 495 | 0.030 |
Why?
|
Epithelial Cells | 1 | 2014 | 141 | 0.030 |
Why?
|
Cell Line | 1 | 2014 | 435 | 0.030 |
Why?
|
Asia | 1 | 2013 | 19 | 0.030 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2012 | 10 | 0.030 |
Why?
|
Phosphorylation | 1 | 2013 | 229 | 0.030 |
Why?
|
Gases | 1 | 2012 | 3 | 0.030 |
Why?
|
Calcium Phosphates | 1 | 2012 | 9 | 0.030 |
Why?
|
Hypoglycemic Agents | 1 | 2014 | 181 | 0.030 |
Why?
|
Reference Values | 1 | 2012 | 246 | 0.030 |
Why?
|
Laos | 1 | 2010 | 3 | 0.020 |
Why?
|
Infusions, Subcutaneous | 1 | 2010 | 4 | 0.020 |
Why?
|
Men's Health | 1 | 2010 | 12 | 0.020 |
Why?
|
Research Design | 1 | 2013 | 315 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2013 | 408 | 0.020 |
Why?
|
Ultrasonography, Interventional | 1 | 2009 | 53 | 0.020 |
Why?
|
Iatrogenic Disease | 1 | 2008 | 15 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2007 | 288 | 0.020 |
Why?
|
Age Distribution | 1 | 2007 | 206 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2006 | 61 | 0.020 |
Why?
|
Statistics as Topic | 1 | 2006 | 108 | 0.020 |
Why?
|
Financing, Organized | 1 | 2005 | 14 | 0.020 |
Why?
|
Professional Practice | 1 | 2005 | 24 | 0.020 |
Why?
|
Apatites | 1 | 2005 | 1 | 0.020 |
Why?
|
Powder Diffraction | 1 | 2005 | 2 | 0.020 |
Why?
|
Convalescence | 1 | 2004 | 2 | 0.020 |
Why?
|
Fluoroscopy | 1 | 2005 | 40 | 0.020 |
Why?
|
Crystallography, X-Ray | 1 | 2005 | 90 | 0.020 |
Why?
|
Education, Medical | 1 | 2005 | 69 | 0.010 |
Why?
|
Critical Pathways | 1 | 2004 | 49 | 0.010 |
Why?
|
Bone Neoplasms | 1 | 2005 | 111 | 0.010 |
Why?
|
Ileum | 1 | 2004 | 15 | 0.010 |
Why?
|
Michigan | 1 | 2003 | 3 | 0.010 |
Why?
|
Tissue Donors | 1 | 2005 | 198 | 0.010 |
Why?
|
Calcium | 1 | 2005 | 307 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2005 | 414 | 0.010 |
Why?
|
Needs Assessment | 1 | 2002 | 76 | 0.010 |
Why?
|
Ultrasonography | 1 | 2004 | 379 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2005 | 1542 | 0.010 |
Why?
|
Mass Screening | 1 | 2003 | 263 | 0.010 |
Why?
|
Registries | 1 | 2002 | 298 | 0.010 |
Why?
|